Amrita Therapeutics is in the vanguard of biotechnology companies translating microbiome technologies into practical tools to benefit patients, with a diverse range of programs at the discovery stage and late preclinical stages.
Our lead cancer peptide therapy AT-01C is a p53 tumor suppressor derived from Mycobacterium Tuberculosis (M. bovis) Protein MPT63 (below), also known as ATP-01.
AT-01C shows tumor-shrinking, anti-metastasis & anti-inflammatory activity in solid tumors including colorectal, bladder and liver cancer, binding to SMAR1 – Scaffold Matrix Attachment Region Binding Protein 1 – for down-regulation of oncogenes with little or no toxicity to healthy tissues. In parallel to clinical development for AT-01C, Amrita Therapeutics is focusing on the 'master-regulator' SMAR1 biomarker as a companion diagnostic test to identify patients most likely to benefit from AT-01C therapy.
Amrita Therapeutics proprietary science platform leverages our increasing understanding of the important role of the microbiome in human health, ushering in a new golden age of drug development.